Wednesday, July 8, 2026

pharma · Hormone Receptor Positive Breast Carcinoma · ER+, HER2- Advanced Breast Cancer · OLMA

Olema Pharmaceuticals

Olema Pharmaceuticals is a pharma organization headquartered in Chennai, IN. It trades on NYSE under ticker OLMA. Primary therapeutic focus areas include Hormone Receptor Positive Breast Carcinoma, ER+, HER2- Advanced Br

Chennai, IN HQ
2 Employees
Public company Type
OLMA · NYSE Ticker
Company details
Status
Public
HQ
Chennai, IN
Employees
2
Programs
7
Drugs
17
Patents
8
Clinical program

Palazestrant

Phase 3 · small molecule · Breast Cancer

Palazestrant for Breast Cancer is a Phase 3 program (small_molecule) at Olema Pharmaceuticals with 3 ClinicalTrials.gov record(s).

← All Olema Pharmaceuticals projects Phase 3 small molecule active

Internal code OP-1250-302

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Olema Pharmaceuticals
Phase
Phase 3
Modality
small_molecule
Indication
Breast Cancer
Status
active
Trials
3